1
22 Deferiprone introducOO in first market The iron chelatiog agent deferiprone ['Keifer'; CiplaJ has been launched in India, its first market [Sc rip 2002: 22, 24 Feb 1995J. Deferiprone is indicated for use in patients with tbalassaemia who have iron accumulation; it is the first oral agent for the management of this condition. Patients with thalassaemia produce insufficient quantities of haemoglobin and erythrocytes. The frequent blood transfusions required to treat the condition can cause an iron overload. and this is a leading cause of premature death in these patients. Every year, around 5000-8000 infants in India, and 100 000 worldwide, are born with this genetic disease, according to Cipla. 11 .... '. INPHARMA- 01&&.2103195109n-00022J$Ol ,orI' Aell. ' ... ...uo",,' Llrnlbtd lH5. All rlghtll r-*

Deferiprone introduced in first market

Embed Size (px)

Citation preview

Page 1: Deferiprone introduced in first market

22 M*RK~-S-Deferiprone introducOO in first market

The iron chelatiog agent deferiprone ['Keifer'; CiplaJ has been launched in India, its first market [Scrip 2002: 22, 24 Feb 1995J.

Deferiprone is indicated for use in patients with tbalassaemia who have iron accumulation; it is the first oral agent for the management of this condition. Patients with thalassaemia produce insufficient quantities of haemoglobin and erythrocytes. The frequent blood transfusions required to treat the condition can cause an iron overload. and this is a leading cause of premature death in these patients.

Every year, around 5000-8000 infants in India, and 100 000 worldwide, are born with this genetic disease, according to Cipla.

11 .... '. INPHARMA- 01&&.2103195109n-00022J$Ol ,orI' Aell. ' ... ...uo",,' Llrnlbtd lH5. All rlghtll r-*